Collplant's collink.3d® bioinks and technologies offer a relevant and timely solution to fda's plan to reduce animal testing in preclinical safety studies

Collplant's novel rhcollagen bioinks are an available solution aligned with fda's plan announced last week to phase out the animal testing requirement for the development of monoclonal antibody therapies and other drug candidates rehovot, israel , april 15, 2025 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), or "collplant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhcollagen for tissue regeneration and medical aesthetics, commented today, following the united states food and drug administration (fda)'s groundbreaking step announced last week to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drug candidates with more effective, human-relevant methods. importantly, collplant's collink.3d ®  portfolio of rhcollagen-based bioink products can be utilized for the biofabrication of tissue-on-a-chip or organ-on-a-chip systems, which serve as alternatives to animal testing.
CLGN Ratings Summary
CLGN Quant Ranking